The landmark SELECT trial recently demonstrated that semaglutide 2.4 mg significantly reduces cardiovascular risks in patients with obesity. However, a new prespecified secondary analysis specifically investigated semaglutide liver fibrosis outcomes in non-diabetic patients. This study focused on individuals at high risk for substantial liver fibrosis. Consequently, researchers evaluated 17,604 participants to determine if the drug provides dual benefits for both the heart and the liver.

They used the Fibrosis-4 (FIB-4) index to identify participants at high risk for liver disease. Notably, patients receiving semaglutide experienced a 21% reduction in major adverse cardiovascular events (MACE) within this high-risk subgroup. This finding is vital because liver disease often worsens the long-term cardiovascular prognosis. Furthermore, the results indicate that the drug remains effective regardless of the baseline liver risk or the severity of hepatic steatosis.

Impact on Semaglutide Liver Fibrosis Outcomes and Enzymes

Moreover, the analysis showed significant improvements in biochemical liver health markers over 104 weeks. Semaglutide effectively lowered alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels throughout the study period. In addition, the fatty liver index decreased significantly in the treatment group compared to the placebo. Therefore, these changes strongly suggest a consistent reduction in the risk of progressive hepatic steatosis and metabolic dysfunction.

Notably, the cardiovascular benefits appeared very early during the trial period. The reduction in MACE occurred largely independently of the magnitude of early weight loss. This suggests that semaglutide provides direct protective effects on the vasculature and metabolic organs. As a result, clinicians should consider these findings when managing patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Such a multi-organ approach ensures better protection for high-risk populations.

Frequently Asked Questions

Does semaglutide help reduce liver fibrosis risk?

Yes, analysis from the SELECT trial shows that semaglutide significantly improves liver enzymes and reduces markers associated with a high risk of liver fibrosis in patients with obesity.

Is semaglutide effective for heart health in patients without diabetes?

The SELECT trial confirmed that semaglutide reduces major adverse cardiovascular events by 20% to 21% in patients with obesity and established heart disease, even if they do not have diabetes.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Meyhöfer SM et al. Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial. Nat Med. 2026 Apr 02. doi: 10.1038/s41591-026-04281-1. PMID: 41928037.

Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi: 10.1056/NEJMoa2306963.

Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. doi: 10.1056/NEJMoa2028395.